{'fraction_non_alphanumeric': 0.031413612565445025, 'fraction_numerical': 0.027923211169284468, 'mean_word_length': 5.597701149425287, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Dolutegravir: A new integrase strand transfer inhibitor for the treatment of HIV

Pharmacotherapy (2014); 34(5): 506–520 The article incorrectly states that participants in the SINGLE study received one of two single-tablet regimens of efavirenz/tenofovir/emtricitabine or dolutegravir/abacavir/lamivudine. The correction is that patients in the dolutegravir arm received a 2 tablet once-daily regimen consisting of dolutegravir 50 mg and a fixed-dosed combination of abacavir and lamivudine. We sincerely apologize for any misunderstanding that this error may have caused.